ESMO GI 2025 at a glance
Get ready for ESMO GI 2025 with LucidQuest’s concise preview, spotlighting must-see sessions and emerging themes in gastrointestinal oncology.
📅 Build your schedule around the topics that interest you. 📥 Download the ESMO GI 2025_Preview_by_LucidQuest
Dive deeper
Key Topics From ESMO GI Scientific Presentations
Biliary Tract Cancer 💧
- CisGem + pembrolizumab: 41% ORR & 61% 6-month PFS.
- Durvalumab: +3.7 months OS vs chemo alone.
Esophageal Cancer 🔥
- RCCEP with camrelizumab flags better OS/PFS.
- Cabozantinib + atezolizumab: 29% ORR.
- RT alone: 23.6-month OS in frail ESCC.
Pancreatic Cancer 🧬
- CERT triplet, lixumistat combos, and caboz-atezo lift PFS/OS.
- NGS reveals targetable mutations in 50% of PDAC.
Gastric Cancer 🥢
- CT041 CAR-T response tied to GZMK⁺ Tpex.
- Nivolumab + chemo: 12.4-month OS.
- Neo-immuno regimens boost pCR in HER2⁺/dMMR disease.
Rectal Cancer 📉
- Sintilimab or nivolumab + TNT: pCR 59–64%.
- Adebrelimab combo: 44% pCR in pMMR LARC.
Gastroesophageal Cancer 🌐
- Givastomig + nivolumab + mFOLFOX: 83% ORR.
- Invikafusp controls 67% of PD-(L)1-resistant GI cases.
Colorectal Cancer 🔄
- Amivantamab rechallenge prolongs PFS/OS in EGFRi-resistant mCRC.
- CD47 mAb ONO-7913 combo shows encouraging left-sided responses.
- PDTO screens guide custom regimens.
Hepatocellular Carcinoma ⚙️
- Irpagratinib + atezolizumab: 52% ORR in FGF19⁺ HCC.
- STRIDE safe in poor-liver-function uHCC.
- Atezo-bev: median OS 20.8 months.
Innovation Spotlight 🚀
BA3182 bispecific shrinks refractory GI ADC tumors.
Low-dose ICIs cut cost & toxicity in MSI-H/dMMR tumors.
Zongertinib active in HER2-driven GI cancers.
ArtificialIntelligence & MachineLearning at ESMO GI 2025
- Muscle-Mass + SIRI Prognosis: AI-CT + inflammation scores predict toxicity & survival in mPDAC. 🏋️♂️
- DL for Gastric Segmentation: 95.8% accuracy, AUC 0.93—beats manual CT reads. 🖥️
- Survival Nets in GC: NN models refine 5-yr prognosis, spotlight chemo benefit. 📊
- AI-Endoscopy: 99% sensitivity/specificity, slashing missed upper-GI lesions. 🔍
- Immune-DL in Colon Cancer: CD3 slide analysis doubles DFS-risk stratification (HR 2.2). 🛡️
- MSI/MMR Prediction: DL AUROC 94% across 2,270 CRC samples—rapid triage tool. ⚡
- cfDNA + AI for HCC: Meta-sensitivity 87%, specificity 89%. 🩸
- Recurrence XGBoost in Rectal Ca: 79.6% accuracy, outperforms TNM staging. 🔄
📅 Build your schedule around the topics that interest you.
📥 Download the ESMO GI 2025_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.